The DCB strategy was created between DT leaving and the...

The DCB strategy was created between DT leaving and the presentation by DCB and Mary was in situ as Chair at that time, so your timeline seems a little off. My concern is that she had neither the experience nor acumen to deal with the implications of the overt Board level conflict and there was significant monies diverted to the DCB strategy that contained various flaws. There was a circa $15m hole in the clinical allocation of which 2 years of overhead addition explains only part. These were both under MH watch. Not the caliber of Chair I want for RAC tbh and do not have confidence in the Chair. PS might be a better option. I personally would not vote to return as Chair.